Definitive Healthcare (NASDAQ:DH) Given New $3.00 Price Target at The Goldman Sachs Group

Definitive Healthcare (NASDAQ:DH - Free Report) had its target price cut by The Goldman Sachs Group from $4.50 to $3.00 in a research note released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other brokerages also recently commented on DH. Stephens initiated coverage on Definitive Healthcare in a research note on Friday, December 20th. They set an "equal weight" rating and a $5.00 target price on the stock. Barclays dropped their price objective on Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating on the stock in a research report on Monday. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $5.35.

Definitive Healthcare Stock Up 8.4 %

NASDAQ:DH traded up $0.22 during trading hours on Tuesday, reaching $2.85. 1,631,450 shares of the company traded hands, compared to its average volume of 985,897. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. The business's 50-day moving average price is $4.52 and its two-hundred day moving average price is $4.44. Definitive Healthcare has a 1 year low of $2.58 and a 1 year high of $8.71. The stock has a market capitalization of $321.80 million, a P/E ratio of -0.92, a P/E/G ratio of 4.06 and a beta of 1.51.

Remove Ads

Definitive Healthcare (NASDAQ:DH - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.04). Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. The company had revenue of $62.29 million during the quarter, compared to analysts' expectations of $60.60 million. Analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current year.

Hedge Funds Weigh In On Definitive Healthcare

Institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its holdings in Definitive Healthcare by 3,652.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company's stock valued at $29,000 after buying an additional 6,794 shares during the last quarter. Bayesian Capital Management LP bought a new stake in shares of Definitive Healthcare during the 4th quarter valued at $41,000. Point72 DIFC Ltd increased its stake in shares of Definitive Healthcare by 759.9% in the 3rd quarter. Point72 DIFC Ltd now owns 9,296 shares of the company's stock worth $42,000 after purchasing an additional 8,215 shares in the last quarter. Ieq Capital LLC bought a new position in Definitive Healthcare in the 4th quarter worth $51,000. Finally, KLP Kapitalforvaltning AS purchased a new position in Definitive Healthcare during the fourth quarter valued at $54,000. Institutional investors own 98.67% of the company's stock.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.